Psychological Medicine
October 17, 2023
Cathy Davies, Matthijs Geert Bossong, Daniel Martins et al.
9 citations
ABSTRACT Background Hippocampal hyperperfusion has been observed in people at Clinical High Risk for Psychosis (CHR), is associated with adverse longitudinal outcomes and represents a potential treatment target for novel pharmacotherapies. Whether cannabidiol (CBD) has ameliorative effects on hippocampal blood flow (rCBF) in CHR patients remains unknown. Methods Using a double-blind,...
Journal of Medicinal Plants Research
October 9, 2023
Kodjo Eloh, Alfa Komi, Oudjaniyobi Simalou et al.
3 citations
Cannabis sativa L. is a widely used recreational drug in Togo, especially among young people. However, little is known about its chemical composition in Sub-Saharan Africa, and specifically in Togo. This study aimed to determine the levels of phytocannabinoids, specifically Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in cannabis samples collected from various towns in Togo using gas...
NEJM evidence
September 2023
Philip E Mosley, Lachlan Webb, Anastasia Suraev et al.
BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There is preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety. METHODS: In this double-blind, crossover trial, participants with severe Tourette syndrome were randomly assigned to a...
Frontiers in Pharmacology
July 31, 2023
Valentina Castelli, Gianluca Lavanco, Cesare D'Amico et al.
Introduction: An altered neurodevelopmental trajectory associated with prenatal exposure to ∆-9-tetrahydrocannabinol (THC) leads to aberrant cognitive processing through a perturbation in the effectors of hippocampal plasticity in the juvenile offspring. As adolescence presents a unique window of opportunity for "brain reprogramming", we aimed at assessing the role of the non-psychoactive...
Phytotherapy Research
July 31, 2023
Giuseppe Tringali, Gianluca Lavanco, Valentina Castelli et al.
17 citations
Alcohol binge drinking is common among adolescents and may challenge the signalling systems that process affective stimuli, including calcitonin gene-related peptide (CGRP) signalling. Here, we employed a rat model of adolescent binge drinking to evaluate reward-, social- and aversion-related behaviour, glucocorticoid output and CGRP levels in affect-related brain regions. As a potential...
Cannabis and Cannabinoid Research
July 26, 2023
Valentina Lorenzetti, Eugene McTavish, Samantha J Broyd et al.
Introduction: Cannabis use is associated with brain functional changes in regions implicated in prominent neuroscientific theories of addiction. Emerging evidence suggests that cannabidiol (CBD) is neuroprotective and may reverse structural brain changes associated with prolonged heavy cannabis use. In this study, we examine how an ∼10-week exposure of CBD in cannabis users affected...
Journal of Exploratory Research in Pharmacology
July 12, 2023
Marilyn Helen Silva
1 citation
Cannabis sativa contains phytocannabinoids that are psychoactive and neurotoxic (delta-9-tetrahydrocannabinol: Δ9THC) or nonpsychoactive and presumptively neuroprotective (cannabidiol: CBD). Along with rising legalization, availability, and demand, the Δ9THC:CBD ratio also has increased. Cannabis legalization means that use will likely increase in pregnant or breastfeeding women, affecting all...
Movement Disorders
July 2023
Christopher H Domen, Stefan Sillau, Ying Liu et al.
Cannabis is increasingly available worldwide but its impact on cognition in Parkinson's disease (PD) is unknown. Present cognitive safety data from study of an oral high-dose cannabidiol (CBD; 100 mg) and low-dose Δ9-tetrahydocannabinol (THC; 3.3 mg) drug in PD. Randomized, double-blind, parallel-group, placebo-controlled study of a CBD/THC drug administered for 16.3 (SD: 4.2) days, with dosage...
The Canadian Journal of Psychiatry
June 27, 2023
Lindsay A. Lo, Caroline A. Maccallum, Kate Nanson et al.
Objective The drug poisoning crisis throughout North America necessitates novel harm reduction approaches. Emerging evidence suggests that cannabidiol (CBD) may have some utility as a harm reduction modality for those with problematic substance use. This rapid review aimed to synthesize available evidence on CBD as a potential harm reduction tool for people who use drugs while providing...
Behavioural Pharmacology
June 1, 2023
Débora A E Colodete, Nicole R Silva, João Francisco C Pedrazzi et al.
Cannabidiol is a phytocannabinoid that lacks the psychotomimetic properties of Δ9-tetrahydrocannabinol (THC), the main psychoactive Cannabis sativa component. Cannabidiol has several potential therapeutic properties, including anxiolytic, antidepressant, and antipsychotic; however, cannabidiol has low oral bioavailability, which can limit its clinical use. Here, we investigated if two...